3d printed drug

BioBot: a Desktop 3D Printer for Living Tissue

Image Posted on Updated on

BioBot: a Desktop 3D Printer for Living Tissue


According to the Biobots,” a Philadelphia based startup has developed a desktop 3D printer for printing biomaterials.  The 3D printer called BioBot 1 was demoed at TechCrunch Disrupt NY in May 2015.  Biobots was found the most innovative startup out of 48 startups at the SXSW Accelerator in Austin.

Biobot 1 uses a compressed air pneumatic system that allows it to precisely control the printing operation.  Biobots has developed biomaterial that is placed in the syringe along with cells for printing.  The biomaterial hardens as it is extruded.  Biobot 1 uses visible blue light to cure the biomaterial.  Unlike UV light, visible blue light is not harmful to living tissue.  The technology can be used to 3D print living tissue such as cartilage, bone, or liver.  The technology can find valuable applications in the clinical development of the drug.

Biobots aims at bringing down the cost of bioprinting significantly.  Typical bioprinters cost in the range of hundred thousand dollars. Biobots managed to bring down the cost by an order of magnitude.  Biobot 1 is also designed for ease of use.  According to Danny Cabrera, co-founder of Biobots, “As soon as you get a BioBot, you can print something. What we’re doing is we’re saying anybody can do this. [It’s] this MakerBot of biology idea.”

http://www.biobots.io/

http://fortune.com/2015/07/13/biobot-the-makerbot-of-biology/

http://techcrunch.com/video/biobots-is-a-3d-printer-for-living-cells/518812512/

http://technical.ly/philly/2015/03/16/biobots-most-innovative-sxsw/

Advertisements

FDA Approves the first 3D Printed Drug from Aprecia Pharmaceuticals

Image Posted on Updated on

FDA Approves the first 3D Printed Drug from Aprecia Pharmaceuticals

—————————————————————————————————–

For the first time, US Food and Drugs Administration (FDA) has approved a 3D printed drug.  According to Aprecia Pharmaceuticals announcement,” that FDA has approved their SPRITAM levetiracetam drug used for certain types of epileptic seizures.  Aprecia uses a ZipDose platform that creates pills by combining multiple layers of powdered medication.  This 3D printing (3DP) technology is based on research performed at the Massachusetts Institute of Technology (MIT).  The 3D printed pill has a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid.  This enables heavy doses of medication to be administered with a small sip of liquid.  This improves the patient experience.  Patients who have difficulty swallowing have a greater chance of missing a dose of the medicine.  Missed dose of medicine often leads to seizures.  Ease of administration of the medication helps manage the diseases better.  According said Don Wetherhold, Chief Executive Officer of Aprecia “By combining 3DP technology with a highly prescribed epilepsy treatment, SPRITAM is designed   to   fill   a  need for   patients who struggle with   their   current   medication experience.”

https://www.aprecia.com/pdf/2015_08_03_Spritam_FDA_Approval_Press_Release.pdf

https://www.aprecia.com/

http://www.spritam.com/

https://www.aprecia.com/zipdose-platform/3d-printing.php